Solifenacin Succinate

WEDNESDAY, Dec. 4, 2024 -- An increase in overactive bladder (OAB) diagnoses was seen following publication of the first OAB guideline, and the rate of third-line therapy procedures also increased, according to a study published online Nov. 19 in Neurourology & Urodynamics . Hodan Mohamud, from the University of Toronto, and colleagues conducted a retrospective cohort study to examine trends in therapy utilization before and after the 2014 American Urological Association/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction OAB guideline amendment and publication of a clinical care pathway in 2016. Patterns of care were assessed from 2013 to 2018. The study included 1,825,782 patients (mean age, 61.1 ± 16.7 years). From 2013 to 2017, the researchers found a 369 percent increase in the number of new OAB diagnoses. Nineteen percent of patients were treated with oral and/or third-line therapies during the six-year study period. The number of oral medications prescribed peaked in 2016, then decreased 17 percent by 2018. The two most prescribed oral medications in 2013 were oxybutynin and solifenacin (46.0 and 31.8 percent, respectively). Mirabegron surpassed solifenacin by 2018 (18.5 versus 16.5 percent), while oxybutynin still accounted for most prescriptions (55 percent). Patients older than 65 years of age filled 80 percent of all initial mirabegron prescriptions. From 2013 to 2018, the rate of third-line therapy procedures nearly doubled (nine to 17 per 1,000 OAB patients). "These trends suggest that OAB therapy guidelines and clinical practice pathways may influence treatment patterns," the authors write. One author disclosed ties to the pharmaceutical industry.

Adamed Pharma is launching its latest combination drug containing an innovative composition of solifenacin and tamsulosin, which is an important addition to the therapies available in the field of pharmacotherapy for urinary tract complaints in men caused by benign prostatic hyperplasia. Adamed Pharma has spent more than five years developing and implementing the drug, which responds to the needs of patients around the world. Adamed Pharma began development of the combination product (modified-release tablets containing solifenacin succinate + tamsulosin hydrochloride) in July 2018. It was an in-depth analysis of patient needs for urological diseases that influenced the decision to develop the drug for such a broad patient population. Indeed, benign prostatic hyperplasia is often a very important life problem for men, negatively affecting both professional and private life. Given the widespread epidemiology of prostatic hyperplasia diseases, the composition of solifenacin with tamsulosin in oral tablet form is the subject of an international patent application of Adamed Pharma (WO2022117594). Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, the small gland that surrounds the male urethra. Benign prostatic hyperplasia is among the most common urological diseases in men and is age-related. According to demographic forecasts by Statistics Poland (GUS), in Poland in 2050, the share of people over the age of 65 will be as high as 32.7%[i], so in the not-too-distant future, many men will live to an age when they develop symptoms of BPH. More than 70% of men over the age of 40 are affected by lower urinary tract complaints.[ii] The latest analysis – conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 – covered 204 countries in the years 2000-2019. It was revealed that there were 94.0 million cases of benign prostatic hyperplasia worldwide in 2019, up from 51.1 million cases in 2000 (70.5% increase in incidence). In Eastern Europe, by contrast, the percentage change in the incidence of BPH was 19.3%, with 49.9% in Poland.[iii]. “We are proud of the results we have achieved in the development of our new value-added product and the process of its launch in the global market. Thanks to the work of the Adamed Research Team and the commitment of our partners, we are introducing a therapy which has a significant impact on the lives and health of patients around the world,” says Sylwia Berdzik-Kalarus, Member of the Management Board of Adamed Pharma S.A., Director of Commercial Affairsand Business Development. The partner involved financially in the development and implementation of this Adamed product is Adalvo, a leading B2B pharmaceutical company in Europe. “Adamed’s mission is to respond to the key challenges of contemporary medicine. As a company founded and still run by doctors, Adamed has always put the well-being of patients first. That’s why we appreciate the cooperation between Adamed and Adalvo, which is based on deep understanding of patients, their needs and expectations,” she adds. Adamed Pharma’s R&D teams continue their R&D efforts to be able to provide patients with new innovative therapies in the future. More than 50 development projects are currently under way at various stages. [i] Polish Agency for Enterprise Development (PARP): Aging of the Population – A Challenge for the Labour Market, Activation of 50+ Employees; https://www.parp.gov.pl/storage/publications/pdf/Starzenie_sie_spoleczenstw.pdf [ii] Coyne K.S., Sexton C.C., Thompson C.L. et al.: The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. Bju International. 2009;104(3):352–360 [iii] Awedew A.F., Han H., Abbasi B. et al.: The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet Healthy Longevity, Volume 3, Issue 11, 2022, Pages e754-e776, ISSN 2666-7568, https://doi.org/10.1016/S2666-7568(22)00213-6